MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-20-2025
Summit Therapeutics Market Cap 2011-2025 | SMMT
As of December 29, 2025 Summit Therapeutics has a market cap of $ 12.9 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Summit Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.5 B | 2.24 B | 286 M | 361 M | 417 M | 195 M | 804 M | 791 M | 390 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.5 B | 195 M | 2.11 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.92 | 14.97 % | $ 490 M |  Britain |
 |
Aclaris Therapeutics
ACRS
|
152 M | $ 3.02 | -0.5 % | $ 233 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.09 | -2.52 % | $ 7.43 B |  Australia |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 1.11 | -2.62 % | $ 6.05 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 211.4 | 1.16 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
BioVie
BIVI
|
2.44 M | $ 1.18 | -2.89 % | $ 1.74 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | USA |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 12.42 | 0.57 % | $ 818 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 0.17 | -20.57 % | $ 370 M |  Israel |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 95.2 | 0.72 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 26.96 | -0.59 % | $ 1.31 B | USA |
 |
Certara
CERT
|
1.98 B | $ 8.85 | -0.51 % | $ 1.42 B | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
960 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
373 M | $ 9.53 | -0.21 % | $ 140 M | USA |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Cellectis S.A.
CLLS
|
203 M | $ 4.93 | 3.79 % | $ 116 M | France |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
39.8 B | $ 581.87 | -0.34 % | $ 44.1 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.55 | 4.08 % | $ 16 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 92.76 | -0.15 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
431 M | - | -0.88 % | $ 598 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 9.25 | 1.82 % | $ 1.49 B | Britain |
 |
CorMedix
CRMD
|
174 M | $ 12.74 | 1.66 % | $ 649 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 25.91 | -1.87 % | $ 1.67 M | USA |